Peter Kirwan

Peter Kirwan

Auto-generated profile, based on publicly available information

Peter Kirwan

University of Cambridge Metabolic Research Laboratories and NIHR Cambridge Biomedical Research Centre, Wellcome Trust-MRC Institute of Metabolic Science, Addenbrooke's Hospital, Cambridge, UK

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 February 2012 in Nature Neuroscience
Verified
Journal Article
Closed access
PDF file
YSYichen Shi
Yichen Shi
PKPeter Kirwan
Peter Kirwan
JSJames Smith
James Smith
HRHugh P C Robinson
Hugh P C Robinson
FLFrederick J Livesey
Frederick J Livesey

7 March 2012 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
YSYichen Shi
Yichen Shi
PKPeter Kirwan
Peter Kirwan
JSJames Smith
James Smith
GMGlenn MacLean
Glenn MacLean
SOStuart H. Orkin
Stuart H. Orkin
FLFrederick J. Livesey
Frederick J. Livesey
Cultured cerebral cortex neurons generated from human Down syndrome induced pluripotent stem cells rapidly develop Alzheimer’s disease pathologies.

1 May 2015 in Cell Reports
Verified
Journal Article
Open access
SMSteven Moore
Steven Moore
LELewis D.B. Evans
Lewis D.B. Evans
TATherese Andersson
Therese Andersson
EPErik Portelius
Erik Portelius
JSJames Smith
James Smith
FLFrederick J. Livesey
Frederick J. Livesey
Accumulation of Aβ peptide fragments of the APP protein and neurofibrillary tangles of the microtubule-associated protein tau are the cellular hallmarks of Alzheimer's disease (AD). To investigate the relationship between APP metabolism and tau protein levels and phosphorylation, we studied human-stem-cell-derived forebrain neurons with genetic forms of AD, all of which increase the release of pathogenic Aβ peptides. We identified marked increases in intracellular tau in genetic forms of AD that either mutated APP or increased its dosage, suggesting that APP metabolism is coupled to changes in tau proteostasis. Manipulating APP metabolism by β-secretase and γ-secretase inhibition, as well as γ-secretase modulation, results in specific increases and decreases in tau protein levels. These data demonstrate that APP metabolism regulates tau proteostasis and suggest that the relationship between APP processing and tau is not mediated solely through extracellular Aβ signaling to neurons.

15 September 2015 in Development
Verified
Journal Article
Open access
PDF file
PKPeter Kirwan
Peter Kirwan
BTBenita Turner-Bridger
Benita Turner-Bridger
MPManuel Peter
Manuel Peter
AMAyiba Momoh
Ayiba Momoh
DADevika Arambepola
Devika Arambepola
FLFrederick J. Livesey
Frederick J. Livesey
A key aspect of nervous system development, including that of the cerebral cortex, is the formation of higher-order neural networks. Developing neural networks undergo several phases with distinct activity patterns in vivo, which are thought to prune and fine-tune network connectivity. We report here that human pluripotent stem cell (hPSC)-derived cerebral cortex neurons form large-scale networks that reflect those found in the developing cerebral cortex in vivo. Synchronised oscillatory networks develop in a highly stereotyped pattern over several weeks in culture. An initial phase of increasing frequency of oscillations is followed by a phase of decreasing frequency, before giving rise to non-synchronous, ordered activity patterns. hPSC-derived cortical neural networks are excitatory, driven by activation of AMPA- and NMDA-type glutamate receptors, and can undergo NMDA-receptor-mediated plasticity. Investigating single neuron connectivity within PSC-derived cultures, using rabies-based trans-synaptic tracing, we found two broad classes of neuronal connectivity: most neurons have small numbers (40). These data demonstrate that the formation of hPSC-derived cortical networks mimics in vivo cortical network development and function, demonstrating the utility of in vitro systems for mechanistic studies of human forebrain neural network biology.

1 June 2014 in Development
Verified
Journal Article
Open access
PDF file
FAFahad R. Ali
Fahad R. Ali
KCKevin Cheng
Kevin Cheng
PKPeter Kirwan
Peter Kirwan
SMSu Metcalfe
Su Metcalfe
FLFrederick J. Livesey
Frederick J. Livesey
APAnna Philpott
Anna Philpott
Generation of neurons from patient fibroblasts using a combination of developmentally defined transcription factors has great potential in disease modelling, as well as ultimately for use in regeneration and repair. However, generation of physiologically mature neurons in vitro remains problematic. Here we demonstrate the cell-cycle-dependent phosphorylation of a key reprogramming transcription factor, Ascl1, on multiple serine-proline sites. This multisite phosphorylation is a crucial regulator of the ability of Ascl1 to drive neuronal differentiation and maturation in vivo in the developing embryo; a phosphomutant form of Ascl1 shows substantially enhanced neuronal induction activity in Xenopus embryos. Mechanistically, we see that this un(der)phosphorylated Ascl1 is resistant to inhibition by both cyclin-dependent kinase activity and Notch signalling, both of which normally limit its neurogenic potential. Ascl1 is a central component of reprogramming transcription factor cocktails to generate neurons from human fibroblasts; the use of phosphomutant Ascl1 in place of the wild-type protein significantly promotes neuronal maturity after human fibroblast reprogramming in vitro. These results demonstrate that cell-cycle-dependent post-translational modification of proneural proteins directly regulates neuronal differentiation in vivo during development, and that this regulatory mechanism can be harnessed to promote maturation of neurons obtained by transdifferentiation of human cells in vitro.

3 June 2020 in Scientific Reports
Verified
Journal Article
Open access
PDF file
TSTakuhiro Sonoyama
Takuhiro Sonoyama
LSLukas K. J. Stadler
Lukas K. J. Stadler
MZMingyan Zhu
Mingyan Zhu
JKJulia M. Keogh
Julia M. Keogh
EHElana Henning
Elana Henning
IFI. Sadaf Farooqi
I. Sadaf Farooqi
Brain-derived neurotrophic factor (BDNF) signals through its high affinity receptor Tropomyosin receptor kinase-B (TrkB) to regulate neuronal development, synapse formation and plasticity. In rodents, genetic disruption of Bdnf and TrkB leads to weight gain and a spectrum of neurobehavioural phenotypes. Here, we functionally characterised a de novo missense variant in BDNF and seven rare variants in TrkB identified in a large cohort of people with severe, childhood-onset obesity. In cells, the E183K BDNF variant resulted in impaired processing and secretion of the mature peptide. Multiple variants in the kinase domain and one variant in the extracellular domain of TrkB led to a loss of function through multiple signalling pathways, impaired neurite outgrowth and dominantly inhibited glutamatergic synaptogenesis in hippocampal neurons. BDNF/TrkB variant carriers exhibited learning difficulties, impaired memory, hyperactivity, stereotyped and sometimes, maladaptive behaviours. In conclusion, human loss of function BDNF/TrkB variants that impair hippocampal synaptogenesis may contribute to a spectrum of neurobehavioural disorders.